481 related articles for article (PubMed ID: 34699020)
1. Healthcare Resource Utilization and Costs of Rivaroxaban Versus Warfarin Among Nonvalvular Atrial Fibrillation Patients with Obesity and Diabetes.
Weir MR; Chen YW; He J; Bookhart B; Campbell A; Ashton V
Diabetes Ther; 2021 Dec; 12(12):3167-3186. PubMed ID: 34699020
[TBL] [Abstract][Full Text] [Related]
2. Healthcare resource utilization and costs of rivaroxaban versus warfarin among non-valvular atrial fibrillation (NVAF) patients with obesity in a US population.
Berger JS; Laliberté F; Kharat A; Lejeune D; Moore KT; Jung Y; Lefebvre P; Ashton V
J Med Econ; 2021; 24(1):550-562. PubMed ID: 33910464
[TBL] [Abstract][Full Text] [Related]
3. Healthcare Resource Utilization and Costs of Rivaroxaban Versus Warfarin Among Non-valvular Atrial Fibrillation (NVAF) Patients with Diabetes in a US Population.
Berger JS; Ashton V; Laliberté F; Germain G; Bookhart B; Lejeune D; Boudreau J; Lefebvre P; Weir MR
Adv Ther; 2023 Mar; 40(3):1224-1241. PubMed ID: 36658454
[TBL] [Abstract][Full Text] [Related]
4. Effect of rivaroxaban versus warfarin on health care costs among nonvalvular atrial fibrillation patients: observations from rivaroxaban users and matched warfarin users.
Laliberté F; Cloutier M; Crivera C; Nelson WW; Olson WH; Schein J; Vanderpoel J; Germain G; Lefebvre P
Adv Ther; 2015 Mar; 32(3):216-27. PubMed ID: 25784509
[TBL] [Abstract][Full Text] [Related]
5. Effects of rivaroxaban versus warfarin on hospitalization days and other health care resource utilization in patients with nonvalvular atrial fibrillation: an observational study from a cohort of matched users.
Laliberté F; Cloutier M; Crivera C; Nelson WW; Olson WH; Schein J; Vanderpoel J; Germain G; Lefebvre P
Clin Ther; 2015 Mar; 37(3):554-62. PubMed ID: 25749196
[TBL] [Abstract][Full Text] [Related]
6. Healthcare resource utilization and expenditures among newly-diagnosed elderly non-valvular atrial fibrillation patients initiating oral anticoagulants.
Chowdhury R; Franchino-Elder J; Wang L; Yuce H; Wang C; Hartaigh BO
J Med Econ; 2019 Dec; 22(12):1338-1350. PubMed ID: 31549883
[No Abstract] [Full Text] [Related]
7. Health Care Resource Utilization and Costs Among Newly Diagnosed and Oral Anticoagulant-Naive Nonvalvular Atrial Fibrillation Patients Treated with Dabigatran or Warfarin in the United States.
Jain R; Fu AC; Lim J; Wang C; Elder J; Sander SD; Tan H
J Manag Care Spec Pharm; 2018 Jan; 24(1):73-82. PubMed ID: 29290177
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness and safety of rivaroxaban versus warfarin among nonvalvular atrial fibrillation patients with obesity and diabetes.
Weir MR; Chen YW; He J; Bookhart B; Campbell A; Ashton V
J Diabetes Complications; 2021 Nov; 35(11):108029. PubMed ID: 34538715
[TBL] [Abstract][Full Text] [Related]
9. Comparative effectiveness, safety, and costs of rivaroxaban and warfarin among morbidly obese patients with atrial fibrillation.
Peterson ED; Ashton V; Chen YW; Wu B; Spyropoulos AC
Am Heart J; 2019 Jun; 212():113-119. PubMed ID: 30981035
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Healthcare Resource Utilization and Costs between Rivaroxaban and Warfarin for Nonvalvular Atrial Fibrillation in a Skilled Nursing Facility Setting.
Mahajan D; Wu B; Song J; Milentijevic D; Ashton V; Mittal VS
Drugs Aging; 2020 Apr; 37(4):281-289. PubMed ID: 32147804
[TBL] [Abstract][Full Text] [Related]
11. Economic burden of rivaroxaban and warfarin among nonvalvular atrial fibrillation patients with obesity and polypharmacy.
Laliberté F; Ashton V; Kharat A; Lejeune D; Moore KT; Jung Y; Lefebvre P; Berger JS
J Comp Eff Res; 2021 Nov; 10(16):1235-1250. PubMed ID: 34378989
[No Abstract] [Full Text] [Related]
12. Influence of Polypharmacy on the Effectiveness and Safety of Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation.
Martinez BK; Baker WL; Sood NA; Bunz TJ; Meinecke AK; Eriksson D; Coleman CI
Pharmacotherapy; 2019 Feb; 39(2):196-203. PubMed ID: 30597611
[TBL] [Abstract][Full Text] [Related]
13. Healthcare resource utilization and costs among nonvalvular atrial fibrillation patients initiating rivaroxaban or warfarin in skilled nursing facilities: a retrospective cohort study.
Mittal VS; Wu B; Song J; Milentijevic D; Ashton V; Mahajan D
Curr Med Res Opin; 2020 Apr; 36(4):529-536. PubMed ID: 31858841
[No Abstract] [Full Text] [Related]
14. Healthcare costs of NVAF patients treated with rivaroxaban and apixaban in the US.
Milentijevic D; Germain G; Laliberté F; Bookhart BK; MacKnight SD; Tsang J; Lefebvre P
J Med Econ; 2020 Nov; 23(11):1365-1374. PubMed ID: 32897766
[TBL] [Abstract][Full Text] [Related]
15. Effect of Apixaban Versus Warfarin Use on Health Care Resource Utilization and Costs Among Elderly Patients with Nonvalvular Atrial Fibrillation.
Deitelzweig S; Luo X; Gupta K; Trocio J; Mardekian J; Curtice T; Lingohr-Smith M; Menges B; Lin J
J Manag Care Spec Pharm; 2017 Nov; 23(11):1191-1201. PubMed ID: 29083968
[TBL] [Abstract][Full Text] [Related]
16. Comparison of all-cause costs and healthcare resource use among patients with newly-diagnosed non-valvular atrial fibrillation newly treated with oral anticoagulants.
Gilligan AM; Franchino-Elder J; Song X; Wang C; Henriques C; Sainski-Nguyen A; Wilson K; Smith DM; Sander S
Curr Med Res Opin; 2018 Feb; 34(2):285-295. PubMed ID: 29166800
[TBL] [Abstract][Full Text] [Related]
17. A rapid evidence assessment of bleed-related healthcare resource utilization in publications reporting the use of direct oral anticoagulants for non-valvular atrial fibrillation.
Shah BR; Scholtus E; Rolland C; Batscheider A; Katz JN; Nilsson KR
Curr Med Res Opin; 2019 Jan; 35(1):127-139. PubMed ID: 30380959
[No Abstract] [Full Text] [Related]
18. Rivaroxaban versus warfarin treatment among morbidly obese patients with venous thromboembolism: Comparative effectiveness, safety, and costs.
Spyropoulos AC; Ashton V; Chen YW; Wu B; Peterson ED
Thromb Res; 2019 Oct; 182():159-166. PubMed ID: 31493618
[TBL] [Abstract][Full Text] [Related]
19. Is rivaroxaban associated with lower inpatient costs compared to warfarin among patients with non-valvular atrial fibrillation?
Laliberté F; Pilon D; Raut MK; Nelson WW; Olson WH; Germain G; Schein JR; Lefebvre P
Curr Med Res Opin; 2014 Aug; 30(8):1521-8. PubMed ID: 24758611
[TBL] [Abstract][Full Text] [Related]
20. Health Care Resource Utilization, Costs, and Persistence in Patients Newly Diagnosed as Having Nonvalvular Atrial Fibrillation and Newly Treated With Dabigatran versus Warfarin in the United States.
Bancroft T; Lim J; Wang C; Sander SD; Swindle JP
Clin Ther; 2016 Mar; 38(3):545-56.e1-6. PubMed ID: 26856927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
